Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision SummitPRNewsWire • 07/10/26
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2SPRNewsWire • 07/07/26
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular PsoriasisPRNewsWire • 05/27/26
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/06/26
Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should KnowZacks Investment Research • 05/05/26
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 YearsPRNewsWire • 05/04/26
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026PRNewsWire • 04/29/26
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM EvidencePRNewsWire • 04/28/26
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review TimelinesPRNewsWire • 04/09/26
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor AgonistsPRNewsWire • 04/08/26
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant MethodsPRNewsWire • 03/19/26
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 YearsPRNewsWire • 03/03/26
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences ConferencePRNewsWire • 02/26/26
Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin DrugBenzinga • 02/25/26
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular PsoriasisPRNewsWire • 02/25/26
Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn't Feel DizzySeeking Alpha • 02/23/26
Vanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia TreatmentBenzinga • 02/23/26